Breast Cancer Drug 'Tamoxifen' Brings Hope To Muscle Disease

NOURAN AMIN | November 22, 2018

article image
Tamoxifen is currently a drug used in the treatment of breast cancer and has been used in patients for many years. Now, the latest research has indicated that Tamoxifen may hold the potential in treating another disease myotubular myopathy by slowing its progression. A severe genetic disease affecting males-- myotubular myopathy weakens all the skeletal muscles from birth leading to paralysis that results in death before two years of age.

Spotlight

Central Drugs Compounding Pharmacy

Central Drugs Compounding Pharmacy is a leading compounding pharmacy dedicated to providing innovative products and comprehensive services to physicians, clinics and their patients in the areas of BHRT, IV Nutrition Therapy, Urology, Weight Loss, Pain Management, Dermatology, and more. With online services and two Southern California locations in Fullerton and La Habra, Central Drugs is passionate about bringing the best in custom solutions, quality products, and customer service since 1999. Our experienced and knowledgeable pharmacists provide the education and resources to promote healthy lives for patients across the country.

OTHER ARTICLES

Roche Prepares to Launch COVID-19 Antibody Test System

Article | April 17, 2020

Swiss pharma giant Roche is joining the race to develop a test for COVID-19 antibodies in people who have been exposed to the disease. This morning, Roche announced the development and upcoming launch of its Elecsys Anti-SARS-CoV-2 serology test to detect antibodies in people who have been exposed to the SARS-CoV-2, the virus that causes COVID-19. Roche is eying May for the launch of the test in Europe and is in talks with the U.S Food and Drug Administration for emergency approval of the system. Antibody testing is central to help identify people who have been infected by the virus, especially those who may have been infected but did not display symptoms, the company said. Roche noted that as more information becomes available about immunity levels to COVID-19, society can return to a sense of normal much more quickly. Roche’s test will join a number of other antibody tests that have recently come on the market. Earlier this month the U.S. Food and Drug Administration approved the first blood test for COVID-19 antibodies.

Read More

How AI and Big Data Will Disrupt Pharma’s Regulatory Compliance Standards

Article | March 4, 2020

The industry as we know it is changing. Pharmaceutical and life sciences companies across the globe are experiencing more pressure than ever to keep up with increased regulatory standards while moving at a pace that requires them to innovate in order to remain competitive. With more real-time automation and the steady increase in AI and Big Data sweeping the landscape, what used to be a slow-to-change and risk-averse industry is now expected to see a significant shift towards newer technology that focus on heightened regulatory standards. Here’s how your company can get ahead of what industry experts are calling, Pharma

Read More

Pharmacist eCare Plan - the newest disrupter in health data exchange?

Article | February 25, 2020

Every member of the health care team shares a common goal of optimizing patient outcomes. Yet each specialty and position of the healthcare team has a unique workflow facilitated by various tools, from an operative report to a progress note. In this regard the pharmacist plays a pivotal function in medication management and requires documentation specific to that role. The Pharmacist eCare Plan (PeCP) allows for an interoperable note to be used in the pharmacy to assist in the exchange of patient information, including active medication list, laboratory results, and payer information. To allow for this, a new type of clinical document architecture for the PeCP was created and standardized for use across pharmacies.

Read More

Clinical Development Risks and Issues in a COVID-19 World

Article | March 20, 2020

Global clinical guidelines have shifted the industry toward risk-based approaches for the planning and execution of clinical trials. The ICH’s guidelines for Good Clinical Practice state that sponsors should evaluate identified risks against existing risk controls by considering “the likelihood of errors occurring, the extent to which such errors would be detectable, and the impact of such errors on human subject protection and reliability of trial results” (ICH E6 R2).

Read More

Spotlight

Central Drugs Compounding Pharmacy

Central Drugs Compounding Pharmacy is a leading compounding pharmacy dedicated to providing innovative products and comprehensive services to physicians, clinics and their patients in the areas of BHRT, IV Nutrition Therapy, Urology, Weight Loss, Pain Management, Dermatology, and more. With online services and two Southern California locations in Fullerton and La Habra, Central Drugs is passionate about bringing the best in custom solutions, quality products, and customer service since 1999. Our experienced and knowledgeable pharmacists provide the education and resources to promote healthy lives for patients across the country.

Events